Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Soft tissue sarcoma, adult
Trial Type:  Treatment
Results 1-25 of 67 for your search:
Start Over
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Phase: Phase III
Type: Treatment
Age: 15 and over
Trial IDs: ALDOXORUBICIN-P3-STS-01, NCI-2014-00753, NCT02049905
Vaccine Therapy and/or Glycosylated Recombinant Human Interleukin-7 after Standard Therapy in Treating Younger Patients with High Risk Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 19 months to 35 years
Trial IDs: 07-C-0206, NCI-2013-01440, 070206, 339168, NCT00526240, P6941, NCT00923351
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Proton Beam Radiation Therapy in Treating Patients With Extremity Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 09510, NCI-2012-00752, NCT01561495
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
Image-Guided Intensity-Modulated Proton Beam Radiation Therapy with Boost in Treating Patients with Primary or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-100, NCI-2012-01931, NCT01659203
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SARC023, NCI-2014-02429, NCT02008877
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, P131392, NCT02054104
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Bevacizumab in Treating Patients With Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 04S1, NCI-2013-01399, NCT00288015
Proton Beam Radiation Therapy in Treating Patients with Previously Untreated Childhood Rhabdomyosarcoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: 04-188, NCI-2011-03349, NCT00592592
Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0192, NCI-2013-01452, 090192, P09512, 8463, NCT00942877
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 11-C-0200, NCI-2013-01496, 110200, P11836, P8875_A21PAMDREVW01, 8875, NCT01391962
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OER-SAR-043, NCI-2011-01314, IRB#11-042, NCT01462630
Gemcitabine Hydrochloride with or without Pazopanib Hydrochloride in Treating Patients with Refractory Soft Tissue Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: 7943, NCI-2012-00052, NCT01532687
Gemcitabine Hydrochloride and Docetaxel or Pazopanib Hydrochloride in Treating Patients with Metastatic, Locally Advanced, or Locally Recurrent Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: 101644, NCI-2012-00675, MUSC 101644, MUSC CTO 101644, PAZ115785, PZP115785, NCT01593748
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC016, NCI-2014-00697, NCT01661283
Start Over